NDRA ENDRA Life Sciences Inc

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14A

(Rule 14a-101)

 

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

 

Proxy Statement Pursuant to Section 14(a) of the Securities

Exchange Act of 1934 (Amendment No. )

 

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material Pursuant to Rule 14a-12

 

ENDRA LIFE SCIENCES INC.

(Name of Registrant as Specified in its Charter)

 

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

 

Payment of Filing Fee (Check the appropriate box):

 

☒ No fee required.

 

☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

(1) Title of each class of securities to which transaction applies: N/A

 

(2) Aggregate number of securities to which transaction applies: N/A

 

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): N/A

 

(4)Proposed maximum aggregate value of transaction: N/A

 

(5) Total fee paid: N/A

 

☐ Fee paid previously with preliminary materials.

 

☒ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

 

(1) Amount Previously Paid: N/A

 

(2) Form, Schedule or Registration Statement No.: N/A

 

(3) Filing Party: N/A

 

(4) Date Filed: N/A

 

 

 

3600 Green Court, Suite 350

Ann Arbor, Michigan 48105

May 17, 2022

 

SUPPLEMENT TO PROXY STATEMENT

FOR THE ANNUAL MEETING OF STOCKHOLDERS

TO BE HELD ON JUNE 22, 2022

 

This proxy statement supplement, dated May 17, 2022, supplements the definitive proxy statement on Schedule 14A (together with subsequent supplements, the “Proxy Statement”) of ENDRA Life Sciences Inc. (the “Company”) that was filed with the Securities and Exchange Commission on May 2, 2022, relating to the Company’s 2022 annual meeting of stockholders to be held on June 22, 2022 (the “2022 Annual Meeting”). Except as specifically supplemented by the information contained in this proxy statement supplement, all information set forth in the Proxy Statement continues to apply and should be considered in voting your shares.

 

Appointment of Proxy Solicitor

 

We have engaged Kingsdale Shareholder Services, U.S. LLC (“Kingsdale”) to assist us with the solicitation of proxies in connection with the 2022 Annual Meeting. We expect to pay Kingsdale a fee of $10,000 plus, in the event Kingsdale is requested to implement a telephone solicitation of shareholders, Kingsdale will be entitled to a fee of $6.00 per call.

 

Stockholders with questions or those who require assistance with respect to the voting should contact Kingsdale at 1-855-476-7868.

 

2